5 completed, 1 terminated. 3 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow ABP-671: new trials by email Literature Review of ABP-671 trials Research Report on ABP-671
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of ABP-671 in Participants With Gout ABP-671, Allopurinol - Gout | Phase 2 / Phase 3 | Terminated | Atom Therapeutics Co., Ltd | 43 | 2024-04-22 | 2025-07-16 |
| Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout ABP-671, Allopurinol, Placebo - Gout | Phase 2 / Phase 3 | Completed | Atom Therapeutics Co., Ltd | 300 | 2023-08-11 | 2025-12-22 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia ABP-671, Placebo - Gout, Hyperuricemia | Phase 2 | Completed | Atom Therapeutics Co., Ltd | 60 | 2020-11-27 | 2023-04-12 |
| Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects ABP-671 - Gout, Food-drug Interaction | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 12 | 2020-05-22 | 2020-06-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 ABP-671, Placebo - Hyperuricemia, Gout | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 27 | 2019-09-05 | 2020-02-12 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects ABP-671, Placebo - Gout, Hyperuricemia | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 32 | 2018-10-17 | 2020-07-29 |
Gout (6) · Hyperuricemia (3)
Atom Therapeutics Co., Ltd (6)
United States (5) · Australia (3) · Georgia (2) · Guatemala (2) · Taiwan (2)
Danielle Armas, M.D. (1) · Danielle Armas, MD (1)